RE:Bracelet OSIn the same way Matt told investors that Aware-1 would take "a few months..".
It's always jam tomorrow... They spin the narrative always to keep up interest. My suspicion is that there were industry doubts around IND-213 results; no-one would pony up the cost of the Phase III - remember. all they had to do was re-run IND-213. If they believed in the data so much, then they should have run it... AND it would be finished by now. They even had a SPA in place, and in calls from that year they spoke about running the phase III by year end..
Then we get the spin... and so we meandered into combining Pela+Pax with a CPI. The issue with this trial is that they will need to show that Pela+Pax+CPI gives a clear survival above and beyond Pela+Pax (which should be seen to repeat the data of IND-213). So there was never any hope of having this differentiation until late 2023/early 2024... so without evidence that the triplet is better, who is going to pay for the Phase III... so no partner, no trial in 2023...
I'm sure (hoipeful) the data next month will be great, but I doubt it will be great enough to bring in a partnership or buyout. And if the Phase III can only be done with a partner, then we won't have a Phase III starting until 2024... and so on it goes...
There is money to be made here, but at current pps, it's too risky for me to invest more.. I'll wait for a pull back to the dollar range.